InnovAge Holding Corp. (INNV) fair value analysis
Nasdaq · Updated 2026-10-19
INNV price how computed
Valuation status
Awaiting full valuationINNV does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $8.85
- Sector
- Healthcare
- 12-month range
- $3.99–$12.11
- Market cap
- $1.21B
- From 52-week high
- -26.9%
- Shares outstanding
- 136M
- Rank in Healthcare by quality score
- #131 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
InnovAge Holding Corp. is a healthcare company that provides integrated care services to Medicare Advantage members, including primary care, behavioral health, pharmacy, and other medical services. The company operates through senior care centers and community-based programs primarily in the western United States.
INNV currently ranks #131 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.21B
- P/E (trailing)
- 22x
- Revenue (TTM)
- $990M
- Net margin
- -0.3%
- EPS (TTM)
- $0.40
- Gross margin
- 21.5%
- Debt / equity
- 0.37
- Revenue growth (3-yr avg)
- 14.5%
- Shares outstanding
- 136M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 25 · oversold
- 50-day average
- $10.14
- 200-day average
- $8.87
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-33.3%)
2026-03 ▲ beat (+240.0%)
2025-12 ▲ beat (+150.0%)
2025-09 ▲ beat (+75.0%)
2025-06 ▲ beat (+24.8%)
2025-03 ▲ beat (+300.0%)
2024-12 ▲ beat (+13.0%)
2024-09 ▼ miss (-100.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 1 hold · 1 sell (3 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $12
- Target vs last price
- +35.6%
What our data shows for INNV
- Our model validated 4 trailing price-to-earnings windows for INNV, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $3.99–$12.11.
- The 14-day relative strength index sits at an oversold 25.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- INNV's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent INNV news
TickrTrends' derived news-sentiment signal for INNV is currently leaning positive, computed from recent coverage.
- InnovAge Holding Corp (INNV) Insider Sale: Chief Legal Officer Nicole Damato Sells 23,814 Shares (gurufocus.com, 2026-09-29)
- InnovAge: Their Care Economics Should Keep Improving Going Forward (NASDAQ:INNV) (seekingalpha.com, 2026-09-26)
- Tech Sector Volatility and Earnings Focus Define Mid-Week Trading Action (thestockmarketwatch.com, 2026-09-23)
What people are saying
Follow the INNV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for INNV showed a shift in the Relative Strength Index this week, moving from the neutral zone into oversold territory. The stock's valuation verdict remains awaiting full valuation as of this reporting period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for INNV show that the Relative Strength Index moved from an oversold zone into a neutral zone during this week. The stock's valuation verdict remains awaiting full valuation. These technical changes suggest a shift in momentum conditions for the Healthcare sector company.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — INNV's relative strength index moved from the neutral zone into oversold territory this week, indicating that the stock has experienced selling pressure according to this momentum indicator. The stock remains in the healthcare sector with a valuation verdict that is currently awaiting full analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is INNV stock undervalued?
INNV does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is INNV's TickrTrends verdict?
INNV is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does INNV compare to other Healthcare stocks?
INNV ranks #131 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is INNV overbought or oversold?
INNV's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does INNV report earnings next?
INNV's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does INNV usually beat earnings estimates?
Over its last 8 reported quarters INNV beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INNV?
Of 3 analysts covering INNV, 1 rate it a buy, 1 a hold and 1 a sell - hold-leaning, with a consensus price target of $12 (+35.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.